Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.

NCT04276597 is registered in ClinicalTrials.gov with Excel Diagnostics and Nuclear Oncology Center as lead sponsor.

NCT NCT04276597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04276597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.
Lead sponsor
Excel Diagnostics and Nuclear Oncology Center
Phase
Phase 2
Overall status
Withdrawn
Start date
March 4, 2020
Completion date
July 15, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine breast tumor, neuroendocrine carcinoma metastatic, neuroendocrine neoplasm of ovary, neuroendocrine skin carcinoma, neuroendocrine tumors, paraganglioma, pheochromocytoma, pulmonary neuroendocrine neoplasm, thymus carcinoid, unknown primary tumors